Retatrutide: What to Know and When You Could Actually Get It

Retatrutide is the most talked-about drug in the GLP-1 world that you cannot get. It has produced the biggest average weight loss ever reported in a large, late-stage obesity trial. It has also not been submitted to the Food and Drug Administration yet. Both of those things are true at the same time, and the gap between them is where most of the confusion online lives.

This page is a tracker. It lays out what retatrutide is, what the trials actually found, what Eli Lilly has said about filing, and what the realistic timeline looks like for a regular person waiting for a prescription.

Nothing here is medical advice. Retatrutide is an investigational drug. Decisions about any weight-management medicine belong with you and a licensed healthcare provider.

What is retatrutide and how is it different?

Retatrutide, currently known by its code name LY3437943, is an injectable drug from Eli Lilly given once a week under the skin [1].

The difference from the drugs already on pharmacy shelves is how many hormone systems it touches:

• Semaglutide (Ozempic, Wegovy, Rybelsus) activates one receptor: GLP-1.
• Tirzepatide (Mounjaro, Zepbound) activates two: GIP and GLP-1.
• Retatrutide activates three: GIP, GLP-1 and glucagon [1].

The glucagon piece is the novel part. Glucagon is usually thought of as the hormone that raises blood sugar, but at these doses the intent is different: it appears to push the body to use more energy, on top of the appetite suppression that GLP-1 and GIP provide. Lilly calls it a “first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist” [1].

How much weight did people lose in the trials?

The pivotal trial is TRIUMPH-1 (NCT05929066), an 80-week, randomized, double-blind, placebo-controlled study in 2,339 adults with obesity, or overweight plus at least one weight-related condition, and without diabetes [1][2]. Participants were randomized to retatrutide 4 mg, 9 mg, 12 mg or placebo.

Lilly reported topline results on May 21, 2026. At 80 weeks, using the efficacy estimand (the analysis that asks what happens to people who stay on treatment as directed) [1][2]:

Dose	Average weight loss at 80 weeks
Retatrutide 4 mg	19.0% (47.2 lbs)
Retatrutide 9 mg	25.9% (64.4 lbs)
Retatrutide 12 mg	28.3% (70.3 lbs)
Placebo	2.2%

Using the treatment-regimen estimand, which counts everyone who was randomized including people who stopped, the same groups came in at 17.6%, 23.7% and 25.0% versus 3.9% for placebo [1]. That difference of roughly 3 percentage points at the top dose is not a technicality. It is the difference between “if you stay on it” and “across everyone who started.”

Two other TRIUMPH-1 findings stood out [1][2]:

• 45.3% of people on 12 mg lost at least 30% of their body weight, a level historically associated with bariatric surgery.
• 65.3% of the 12 mg group ended the trial with a BMI under 30, including 37.5% of those who started with class 3 obesity (BMI of 40 or above).
• Average waist circumference at 12 mg fell by 24.1 cm, about 9.5 inches.

There was also a prespecified blinded extension for 532 participants who started with a BMI of 35 or higher. Those who continued on the 12 mg pathway to 104 weeks lost an average of 30.3%, or 85.0 pounds [1][2].

What about people with diabetes and heart disease?

On July 23, 2026, Lilly reported two more Phase 3 results [3][4]:

• TRIUMPH-2 (n=1,152), in adults with obesity or overweight plus type 2 diabetes: average weight loss of 12.7% (29.8 lbs), 19.1% (45.4 lbs) and 20.8% (49.6 lbs) at 80 weeks for 4 mg, 9 mg and 12 mg, versus 4.0% for placebo, with A1C down as much as 1.6 points.
• TRIUMPH-3 (n=1,949), in adults with a BMI of 35 or higher plus established cardiovascular disease: 21.6% at 9 mg and 22.6% at 12 mg, up to 55.8 pounds, versus 3.2% for placebo.

Those numbers are lower than TRIUMPH-1’s, which is expected. People with type 2 diabetes typically lose less weight on incretin drugs, and the TRIUMPH-3 population was sicker. TRIUMPH-4, reported in December 2025 in adults with knee osteoarthritis, showed 28.7% at 68 weeks.

What are the side effects?

Retatrutide’s side-effect profile looks like the rest of the class, with one extra wrinkle.

In TRIUMPH-1 at the 12 mg dose, the most common adverse events were nausea (42.4%), diarrhea (32.0%), constipation (26.1%) and vomiting (25.3%), most of them mild to moderate and clustered during dose escalation [2].

Discontinuation because of side effects tracked closely with dose [1][2]:

Dose	Stopped because of side effects
4 mg	4.1%
9 mg	6.9%
12 mg	11.3%
Placebo	4.9%

The extra wrinkle is dysesthesia, an altered or tingling skin sensation. It was reported in 12.5% of the 12 mg group in TRIUMPH-1 and has shown up across the retatrutide program [2]. It is worth noting that the FDA said it is separately investigating the same type of reaction seen more often with high-dose semaglutide (Wegovy HD), so this is a class question, not a retatrutide-only question.

When will retatrutide be approved?

Here is the part most articles get wrong. Positive Phase 3 results are not an approval, and they are not even an application.

In its July 23, 2026 announcement, Lilly said it “is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval” [3][4].

Three things follow from that sentence:

1. Nothing has been filed yet. As of September 14, 2026, the FDA had no retatrutide application to review.
2. It is a BLA, not an NDA. Retatrutide is regulated as a biologic, so the application type differs from a small-molecule pill like orforglipron.
3. The holdup is manufacturing paperwork, not the trial data. Secondary coverage has framed the Q1 2027 date as a slip from an earlier expectation of a 2026 submission, tied to the CMC package [1].

Once a complete application is filed, the FDA says it has “6 to 10 months to make a decision on whether to approve the drug” [5]. Applying that to a Q1 2027 filing:

• Priority review scenario: decision in the second half of 2027.
• Standard review scenario: decision in the first half of 2028.
• Launch: typically one to three months after approval.

Those are estimates based on published FDA timelines, not Lilly guidance. Filings slip. The FDA can issue a Complete Response Letter asking for more. Treat any confident “retatrutide launches in month X” claim you see online as marketing.

Is retatrutide better than Zepbound?

On paper, 28.3% beats tirzepatide’s roughly 20% to 22% in its own trials. But comparing across separate trials is unreliable: different populations, different lengths, different estimands, different placebo effects.

The honest answer is that a real head-to-head exists. Lilly is running a Phase 3 study of retatrutide compared with tirzepatide in 800 adults with obesity (TRIUMPH-5, NCT06662383). As of September 14, 2026 the registry listed it as active and no longer recruiting, with primary completion scheduled for November 2026 — that is, still ahead, not behind [6]. When those results are reported, that will be the first fair comparison. Until then, anyone claiming to know how retatrutide compares with tirzepatide head-to-head is extrapolating.

There is also a large cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes (NCT06383390), enrolling 10,000 people with primary completion scheduled for February 2029 [7]. Outcomes data of that kind is what eventually drives insurance coverage, so it matters even though it is years away.

Can you get retatrutide now?

There are three answers, and only two of them are legitimate.

The first legal route is a clinical trial. Most retatrutide studies have completed enrollment, but some remain open. As of September 2026, the SYNERGY-Outcomes master protocol in metabolic dysfunction-associated steatotic liver disease (NCT07165028) was recruiting, with a planned enrollment of 4,500 [8]. Search “retatrutide” at clinicaltrials.gov, filter to recruiting studies near you, and contact the site coordinator listed under Contacts and Locations. Lilly also runs its own study finder at trials.lilly.com.

The second legal route is expanded access, and it is narrow. In June 2026 Eli Lilly registered a pre-approval single-patient expanded access program for retatrutide, listed on ClinicalTrials.gov as NCT07629401 with a status of Available [11]. This is what people usually mean by “compassionate use.” The published criteria are strict: you must be 18 or older, have a BMI of 35 or higher despite taking and tolerating the highest available dose of an approved chronic weight management therapy, have two or more serious or life-threatening obesity-related complications that are currently being treated, be unable to join a retatrutide trial or a comparable trial because of eligibility rules or because no site is reachable, and have already discussed all standard options including bariatric surgery.

You cannot apply on your own behalf. A treating physician contacts Lilly (ClinicalTrials@lilly.com or 1-800-545-5979), then files a single-patient application with the FDA, and an institutional review board has to approve the plan. Lilly can decline for any reason. If you think you might meet those criteria, the next step is a conversation with your own physician, not a form you fill out.

The route to avoid is buying vials online. Retatrutide is sold by “research chemical” and peptide vendors. Those products are not FDA-approved, are not manufactured to pharmaceutical standards, and are not tested for sterility, purity or dose accuracy. Because retatrutide is not approved anywhere in the world, there is no legitimate pharmaceutical supply that could have leaked into the gray market. The FDA has repeatedly warned consumers about unapproved GLP-1 products sold for weight loss [9].

Compounding pharmacies also cannot legally compound retatrutide: compounding rules are built around approved active ingredients, and retatrutide is not one.

What should you actually do while you wait?

If you are waiting for retatrutide, you are waiting at least a year and probably longer. A few practical points, none of which are medical advice:

• Approved options already exist, including semaglutide (Wegovy, Wegovy HD, the Wegovy pill), tirzepatide (Zepbound) and orforglipron (Foundayo). A provider can tell you whether any of them fits your situation.
• Trial participation is free to the participant and usually includes a stipend for time and travel, but you may be randomized to placebo.
• Set a registry alert rather than refreshing news sites. ClinicalTrials.gov lets you save a search for “retatrutide” and be notified when new studies post.

Retatrutide at a glance

Item	Status as of 2026-09-14
FDA status	Investigational; not submitted
Mechanism	GIP, GLP-1 and glucagon triple agonist
Route	Once-weekly subcutaneous injection
Doses studied	4 mg, 9 mg, 12 mg
Best reported weight loss	28.3% at 80 weeks; 30.3% at 104 weeks in an extension
Planned filing	Biologics License Application, Q1 2027
Earliest realistic decision	Late 2027 (estimate)
Open trials	Limited; SYNERGY-Outcomes (NCT07165028) recruiting

Sources

1. Eli Lilly, “Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial,” May 21, 2026 — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
2. AJMC, “Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial,” May 21, 2026 — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
3. Eli Lilly, “Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials,” July 23, 2026 — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
4. PR Newswire mirror of the July 23, 2026 release — https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
5. FDA, “Step 4: FDA Drug Review” — https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
6. ClinicalTrials.gov, NCT06662383 (TRIUMPH-5, retatrutide versus tirzepatide) — https://clinicaltrials.gov/study/NCT06662383
7. ClinicalTrials.gov, NCT06383390 (TRIUMPH-Outcomes) — https://clinicaltrials.gov/study/NCT06383390
8. ClinicalTrials.gov, NCT07165028 (SYNERGY-Outcomes) — https://clinicaltrials.gov/study/NCT07165028
9. FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
10. ClinicalTrials.gov, NCT05929066 (TRIUMPH-1) — https://clinicaltrials.gov/study/NCT05929066
11. ClinicalTrials.gov, NCT07629401 (retatrutide pre-approval expanded access) — https://clinicaltrials.gov/study/NCT07629401